Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Aclaris Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 98 | 1 | 81 | −16 |
| Shares | 52.9M | 2.03M | 50.9M | +74.7K (+0.1%) |
| Value | $58.1M | $2.24M | $58.5M | +$2.63M (+4.7%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,711,797 | $1.97M | 0.00% |
| Jacobs Levy Equity Management, Inc | 915,509 | $1.05M | 0.00% |
| Assenagon Asset Management S.A. | 185,777 | $213.6K | 0.00% |
| ADAR1 Capital Management, LLC | 90,000 | $103.5K | 0.02% |
| Shay Capital LLC | 27,000 | $31.1K | 0.01% |
| AJOVista, LLC | 17,455 | $20.1K | 0.09% |
| Two Sigma Securities, LLC | 10,740 | $12.4K | 0.00% |
| Advisor Group Holdings, Inc. | 1,732 | $1.99K | 0.00% |
| Truvestments Capital LLC | 150 | $173 | 0.00% |
Sold out (25)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,000,000 | $1.10M |
| AQR Capital Management LLC | 386,177 | $424.8K |
| Charles Schwab Investment Management Inc | 260,706 | $286.8K |
| Alpine Global Management, LLC | 177,909 | $195.7K |
| Man Group plc | 118,459 | $130.3K |
| Centiva Capital, LP | 117,966 | $129.8K |
| Y-Intercept (Hong Kong) Ltd | 114,806 | $126.3K |
| Verition Fund Management LLC | 82,883 | $91.2K |
| HRT Financial LP | 81,005 | $89.0K |
| Paloma Partners Management Co | 79,200 | $87.1K |
| Deuterium Capital Management, LLC | 72,091 | $79.3K |
| Rhumbline Advisers | 42,005 | $46.2K |
| Mirae Asset Global ETFs Holdings Ltd. | 35,794 | $39.4K |
| Schonfeld Strategic Advisors LLC | 35,300 | $38.8K |
| XTX Topco Ltd | 24,452 | $26.9K |
| Jump Financial, LLC | 22,524 | $24.8K |
| Balyasny Asset Management LLC | 13,910 | $15.3K |
| ProShare Advisors LLC | 13,701 | $15.1K |
| Virtu Financial LLC | 11,622 | $13.0K |
| Baader Bank INC | 10,466 | $9.38K |
| Group One Trading, L.P. | 5,549 | $6.10K |
| Macquarie Group Ltd | 3,497 | $3.85K |
| New York State Common Retirement Fund | 586 | $645 |
| Innealta Capital, LLC | 56 | $62 |
| Covestor Ltd | 62 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,032,155 | $2.24M |